59 results
DEF 14A
NMRA
Neumora Therapeutics Inc.
25 Apr 24
Definitive proxy
4:05pm
) the nature of any substantive amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer … , principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
EU regulatory systems, we must submit a MA application (MAA). The process for doing this depends, among other things, on the nature of the medicinal … candidates and building the technologies related to the clinical development of our product candidates. Given the specialized nature of brain diseases
10-K
2023 FY
EX-10.22
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
discretion of the Company (subject to any ramification such changes may have under Section 6 of this Agreement). This “at-will” nature of Executive’s
10-K
EX-10.23
f14 ezuricuw1aep
7 Mar 24
Annual report
4:05pm
10-Q
86obbn17am9v
1 Nov 23
Quarterly report
4:05pm
S-8
EX-99.1
d79dg0l7qdhm94bmy
19 Sep 23
Registration of securities for employees
9:57pm
8-K
EX-3.2
6q3ejf2sco00
19 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:16pm
424B4
gf5gb j644m5ksvzy7zr
18 Sep 23
Prospectus supplement with pricing info
4:12pm
S-1/A
dxa f3zad4
11 Sep 23
IPO registration (amended)
6:07am
S-1/A
EX-1.1
cb7eug8
11 Sep 23
IPO registration (amended)
6:07am
S-1/A
EX-10.13
veb7l9
11 Sep 23
IPO registration (amended)
6:07am
S-1
EX-10.14
ir66w2d gx
25 Aug 23
IPO registration
5:03pm
S-1
EX-2.1
334dn0xm4d72vgw
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.6
zshx12yk2id2xtmn5g
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.19
qvsifa4rg5 v2xsgg3ot
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.17
7h5fa
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.4
rqdwisjilhqos 1ag
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.11
yf28qhxj
25 Aug 23
IPO registration
5:03pm